Abstract
As psoriasis and psoriatic arthritis are chronic in nature, ideal treatment should have sustained efficacy, with minimal short- and long-term toxicities to allow lifelong treatment. Traditional therapies used for psoriatic arthritis or psoriasis, including phototherapies and systemic agents, do not satisfy these criteria. Ninety percent of patients surveyed in 1998 by The National Psoriasis Foundation were not satisfied with their treatment options.
Several observations have supported the introduction of the tumor necrosis factor (TNF) antagonist etanercept as a treatment for psoriatic disease, including the failure of traditional therapies to meet patient needs, evidence that TNF plays a fundamental role in the inflammatory processes underlying psoriatic arthritis and psoriasis, and the safety and efficacy of this agent in other inflammatory, immune-mediated diseases, such as rheumatoid arthritis (RA). Etanercept prevents initiation of the proinflammatory cascade by competitively binding TNF. First indicated for RA, etanercept is also approved for the treatment of psoriatic arthritis, juvenile RA, ankylosing spondylitis, and most recently psoriasis.
Etanercept provides dermatologists with a safe, effective, and convenient treatment option for patients with psoriatic arthritis and psoriasis, which can be used continuously with or without traditional therapies. The self-administered injections provide a distinct advantage over traditional therapies that often require frequent office visits and laboratory monitoring, and other biologic agents that require administration in the doctor’s office. Dermatologists should be aware of the ongoing research with etanercept in psoriasis and other dermatologic conditions.
Similar content being viewed by others
References
National Psoriasis Foundation. Facts overview. Available from URL: http://www.psoriasis.org/facts/psoriasis [Accessed 2003 Dee 15]
National Psoriasis Foundation. Facts: psoriatic arthritis. Available from URL: http://www.psoriasis.org/facts/psoriasis [Accessed 2003 Dee 15]
Boumpas DT, Illei GG, Tassiulas I. Psoriatic arthritis. In: Klippel JH, Crofford L, Stone JH, et al., editors. Primer on the rheumatic diseases. Atlanta (GA): Arthritis Foundation, 2001: 233
Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. J Am Acad Dermatol. 2001; 137: 280–4
Lebwohl M, Ali S. Treatment of psoriasis. Part 1: topical therapy and phototherapy. J Am Acad Dermatol. 2001; 45: 487–502
Therapeutic treatment options. In: Lebwohl MG, Feldman SR, Koo JYM, et al., editors. Psoriasis: treatment options and patient management (handbook of the National Psoriasis Foundation). A product of the Psoriasis Consensus Meeting; 2002 Mar 8-10; Miami Beach (FL). Portland (OR): National Psoriasis Foundation, 2
Stern RS, Laird N, Melski J, et al. Cutaneous squamous cell carcinomas in patients treated with PUVA. N Engl J Med. 1984; 310: 1156–61
Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997; 336: 1041–5
Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Eng1J Med. 2003; 349: 658–65
Jeffes III EWB, McCollough JL, Pittlekow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995; 104: 183–8
Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol. 2004; 50: 301–9
Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999; 38: 241–51
Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002; 46: 1–23
Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-1R in psoriatic arthritis synovial fluid. J Rheumatol. 1998; 25: 105–10
Nickoloff BJ, Karabin GD, Barker K, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991; 138: 129–40
Terajima S, Higaki M, Igarashi Y, et al. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res. 1998; 290: 246–52
Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994; 96: 146–51
Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998; 25: 1544–52
Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997; 11: 115–8
Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin Exp Dermatol. 1994; 19: 383–7
Moreland LW, Schiff MH Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999; 130: 478–86
Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fe fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253–9
Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003; 48: 1493–9
Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002; 46: 1443–50
Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342: 763–9
Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003; 48: 218–26
Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346: 1349–56
Calin A, Dijkmans BAC, Emery P, et al. A multicentre, placebo-controlled trial of Enbrel in ankylosing spondylitis [abstract]. Ann Rheum Dis. 2003; 62 Suppl. 1: OP0097
Davis JC, Van der Heijde D, Braun J. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2003; 48: 3230–6
Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000; 356: 385–90
Mease PJ, Kivitz A, Burch F, et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrelf): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum. 2001; 44 Suppl. S90: 226
Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–72
Ory P, Sharp IT, Salonen D, et al. Etanercept (Enbrel©) inhibits radiographic progression in patients with psoriatic arthritis [abstract no. OP0089]. Ann Rheum Dis. 2003 Jul; 62 Suppl. 1: 92–3
Piquet PF, Gran GE, Vasseli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol. 1990; 136: 103–10
Murloch M, Navaseria H, Balkwell F, et al. Tumor necrosis factor and psoriasis [abstract]. Br J Dermatol. 1989; 119 Suppl. 33; 46
Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139: 1627–32
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349: 2014–22
Gottlieb AB, Gordon KB, Wang AT, et al. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response [abstract]. J Am Acad Dermatol. 2004; 50: P146
Leonardi CL, Elewski BE, Camisa C, et al. The efficacy and safety of etanercept in the retreatment of psoriasis after relapse [abstract]. J Am Acad Dermatol. 2004; 50: P146
Elewski BE, Bob E, Papp K, et al. Efficacy and safety of etanercept inpatients with psoriasis: results of a global phase 3 study [abstract]. J Am Acad Dermatol. 2004; 50: P159
Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf. 2002; 25: 173–97
Ellman MH MacDonald PA, Hayes FA, et al. Etanercept as a treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum. 2000; 43 Suppl.: S392
Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF pathway: use of infiiximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002; 132: 414–22
Kovach BT, Calamia KT, Walsh JS, et al. Treatment of multicentric reticulohistocytosis with etanercept. Arch Dermatol. 2004; 140: 919–21
Labrecque P, Null M. Cicatricial pemphigoid and therapy with the TNF inhibitor etanercept [abstract]. J Am Acad Dermatol. 2004; 50: P48
Querfeld C, Guitart J, Kuzel J, et al. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept. Arch Dermatol. 2004; 140: 1539–40
Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003; 72: 396–8
Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002; 205: 213–6
Cohen DJ. Successful treatment of pyoderma gangrenosum with etanercept [poster]. Academy Meeting of the American Academy of Dermatology; 2004 Jul 28–Aug 1; New York
Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis and skin disease. J Rhematol. 2003; 30: 1864–7
Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003; 139: 1259–62
Jurgensmeyer JC. Clinical improvement of refractory hidradenitis with etanercept [abstract]. J Am Acad Dermatol. 2004; 50: P15
Enbrel [package insert]. Thousand Oaks (CA): Amgen, 2004
Sabath DR, Homan J, Wallis WJ, et al. Serious infection reports with etanercept (ENBREL©) [abstract]. Ann Rheum Dis. 2002; 61 Suppl. 1: OP0099
Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002; 359: 579–80
Humim [package insert]. Abbott Park (IL): Abbott Laboratories, 2004
Remicade [package insert]. Malvern (PA): Centocor Inc., 2003
Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004; 39: 295–9
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41: 401–7
Keystone E, Schiff M, Kremer J, et al. Once weekly administration of 50mg etanercept (ENBREL©): a phase 3 clinical trial [abstract]. Arthritis Rheum. 2003; 48 Suppl. S653: 1707
Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001; 28: 1238–44
Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46: 850–60
Acknowledgments
The author is a consultant and investigator for Amgen; Abbott Laboratories; Genentech Inc.; Centocor Inc.; and Biogen Inc. Preparation of this manuscript was funded by Amgen.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lebwohl, M.G. Use of Etanercept in the Dermatology Setting. Am J Clin Dermatol 6, 49–59 (2005). https://doi.org/10.2165/00128071-200506010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200506010-00006